Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JNJ
JNJ
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
J&J Seeks Expanded Use of Lung Cancer Drug Rybrevant
Yahoo/Zacks.com
JNJ
Rybevant
non-small cell lung cancer
AstraZeneca
Tagrisso
Flag link:
Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
Johnson & Johnson Is Eyeing Intuitive Surgical's Market, But Can It Win?
Motley Fool
JNJ
Intuitive Surgical
Medtech
robotic surgery
Flag link:
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Astellas pays $175M for Propella, clearing early-phase rival to J&J's Zytiga for takeoff
Fierce Biotech
Astellas
Propella Therapeutics
M&A
JNJ
Zytiga
prostate cancer
Flag link:
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
Fierce Pharma
JNJ
Bayer
Xarelto
blood thinners
AHA
peripheral artery disease
Flag link:
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis
Biopharma Reporter
Janssen
JNJ
rheumatoid arthritis
nipocalimab
clinical trials
Flag link:
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
J&J books manufacturing space at Fujifilm Diosynth's upcoming mega-plant in North Carolina
Fierce Pharma
JNJ
Janssen
Fujifilm Diosynth Biotechnologies
CDMOs
North Carolina
Flag link:
J&J targets 2024 for Ottava FDA filing
J&J targets 2024 for Ottava FDA filing
Medtech Dive
JNJ
Medtech
Ottava
robotic surgery
Flag link:
HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations
HHS Considers Removing J&J’s Stelara from Medicare Drug Price Negotiations
BioSpace
JNJ
Stelara
HHS
Inflation Reduction Act
Medicare
drug pricing
Flag link:
Study of Johnson & Johnson device shows promising results for AFib
Study of Johnson & Johnson device shows promising results for AFib
Clinical Trials Arena
JNJ
Medtech
QDOT MICRO
atrial fibrillation
Flag link:
Amgen scores FDA approval for Stelara biosimilar
Amgen scores FDA approval for Stelara biosimilar
Pharmaceutical Technology
Amgen
Stelara
biosimilars
JNJ
FDA
Wezlana
Flag link:
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
GSK to pay $1 bln for exclusive license to J&J's hepatitis B therapy
Reuters
GSK
JNJ
hepatitis B
JNJ-3989
Janssen
Flag link:
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Cidara’s J&J-partnered immunotherapy could target flu and cancer
Pharma Voice
Cidara
JNJ
immunotherapy
drug-Fc conjugates
cancer
Flu
Flag link:
Janssen reports data from Phase III trial of lung cancer drug
Janssen reports data from Phase III trial of lung cancer drug
Clinical Trials Arena
JNJ
Janssen
Rybrevant
clinical trials
non-small cell lung cancer
Flag link:
J&J bites back against dengue, linking antiviral to protection from infection in challenge trial
J&J bites back against dengue, linking antiviral to protection from infection in challenge trial
Fierce Biotech
JNJ
dengue
JNJ-1802
antiviral
Flag link:
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Flag link:
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?
Medical Marketing and Media
JNJ
Rybrevant
AstraZeneca
Tagrisso
EGFR-mutated NSCLC
Flag link:
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
Fierce Pharma
JNJ
Legend Biotech
Multiple Myeloma
CAR-T
Carvykti
cell therapy
Flag link:
Why Johnson & Johnson Stock Flopped Today
Why Johnson & Johnson Stock Flopped Today
Motley Fool
JNJ
earnings
analysts
Flag link:
J&J Signals Exit from Less Profitable Orthopedic Markets
J&J Signals Exit from Less Profitable Orthopedic Markets
Medical Devices and Diagnostics Industry
JNJ
Medtech
Orthopedics
Flag link:
J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance
J&J Sees Nearly 7% Growth in Q3, Increases Full-Year Guidance
BioSpace
JNJ
earnings
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »